NCT04068168 (Imfinzi PMS) is a clinical trial in Lung Cancer, Biliary Tract Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT04068168?

NCT04068168 is sponsored by AstraZeneca.

What condition does NCT04068168 study?

NCT04068168 studies Lung Cancer, Biliary Tract Cancer.

Is NCT04068168 still recruiting?

NCT04068168 is currently completed. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT04068168: Imfinzi PMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

Completed Last updated 17 November 2025

What this trial tests

trial in Lung Cancer, Biliary Tract Cancer in 712 participants. Completed in 27 December 2024.

Timeline

30 January 2020

Primary endpoint
27 December 2024

27 December 2024

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	712
Start date	30 January 2020
Primary completion	27 December 2024
Estimated completion	27 December 2024
Sites	24 locations across South Korea

Conditions studied

Lung Cancer, Biliary Tract Cancer — all drugs for Lung Cancer, Biliary Tract Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Lung Cancer, Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04068168 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04068168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing